Guillaume Mottet | Lab Head
Sanofi
After completing his Ph.D. studies in 2009 in microfluidic chip field, he continued as postdoctoral fellow at Institut Curie in the team of Jean Louis Viovy and developed thermoplastic chips for diagnostics. In 2013, he went on to apply droplet microfluidics for the study of molecular evolution in the lab of Andrew Griffiths at ESPCI, and in 2015 he joined the team of Pierre Bruhns at Institut Pasteur, where he implemented a single-cell droplet microfluidic platform for high throughput B cell analysis. Now at Sanofi, he is taking on a leading role in the microfluidics team with the goal to develop new technology for drug discovery.
Appearances:
Festival of Biologics Day 2 @ 17:50
Antibody Secreting Cells Repertoire for Drug Discovery, Potential & Reality
Drug therapies based on Monoclonal Antibodies are an incontestable success for patients, but the rapid generation of potent antibodies remains a challenge. Secreted antibodies from ASC appear to be promising but require new technologies to be addressed and have yet to demonstrate a clear advantage over traditional display antibodies. To interrogate the antibody secreting cells (ASC) repertoire we optimized a single cell droplet microfluidic pipeline to increase the robustness. For the display antibody repertoire, we used the traditional pipeline based on single B cell (sBC) technology that combines the use of a FACS (Fluorescent Active Cell Sorting) and scRT-PCR (single cell Reverse Transcriptase PCR). We also evaluated an optimization of this sBC pipeline by replacing the scRT-PCR by a scRNA-Seq based on a 10x Genomics. Based on these two pipelines, we elaborated a head-to-head comparison of the antigen affinity of their respective antibodies.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events